Teladoc Health, Inc. - TDOC STOCK NEWS

Teladoc Health reported a strong fourth quarter in 2022, with revenue increasing by 15% year-over-year to $637.7 million and an 18% rise for the full year to $2,406.8 million. Despite this growth, the company faced a substantial net loss of $3.81 billion in Q4 and $13.66 billion for the year, primarily due to non-cash goodwill impairment charges. Adjusted EBITDA rose 22% to $94.1 million in Q4, indicating operational efficiency. Looking ahead, Teladoc projects revenue between $2.55 and $2.68 billion for 2023, with expectations of reducing net losses per share significantly.

Teladoc Health, Inc. (NYSE: TDOC) will release its fourth quarter 2022 results on February 22, 2023, after market close. The company plans to host a conference call at 4:30 p.m. E.T. to discuss the results. U.S. participants can access the call at 1-844-200-6205, while international participants can dial 1-929-526-1599 using access code # 033061. A live audio webcast will also be available online. A replay will be accessible shortly after the call and will remain available for approximately 90 days. Teladoc is a leader in whole-person virtual care, providing transformative healthcare experiences to improve health outcomes.

Teladoc Health has published its third annual corporate social responsibility report, showcasing a commitment to health equity and community well-being. Highlights include a 33% increase in employee volunteerism, financial aid of $18 million for low-income therapy costs, and the deployment of 18 telehealth devices to Ukraine. The report signifies a landmark year for the company, marking its 50 millionth visit and 20th anniversary in 2022. CEO Jason Gorevic emphasizes the mission to empower healthier communities through equitable quality care. The full report is available online.

Teladoc Health has launched a new comprehensive digital application to provide a fully integrated health care experience, offering seamless access to primary care, mental health, and chronic condition management. The app will support both English and Spanish speakers, catering to the 40 million Spanish speakers in the U.S. The company has expanded its network with over 100 Spanish-speaking providers, showing early positive impacts on user satisfaction. The integrated experience emphasizes comprehensive care by addressing physical, mental, and socioeconomic needs.

Teladoc Health (NYSE: TDOC) will have CEO Jason Gorevic and CFO Mala Murthy participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 9, 2023. The event will feature a live audio webcast and a replay of their presentation, enhancing accessibility for stakeholders. Teladoc Health is recognized as a leader in whole-person virtual care, focusing on transforming the healthcare experience by using proprietary health signals and personalized interactions to improve outcomes across all health stages.

Teladoc Health (NYSE: TDOC) will have CEO Jason Gorevic and CFO Mala Murthy participate in the Piper Sandler 34th Annual Healthcare Conference in New York on November 30, 2022. This prominent event will showcase Teladoc's leadership in whole-person virtual care. A live audio webcast and replay of their presentation will be accessible through Teladoc's investor relations website. As a leader in virtual healthcare, Teladoc Health focuses on improving health outcomes using innovative technology and data-driven insights.

Teladoc Health (TDOC) announced a milestone of surpassing 50 million visits delivered through its global network of clinicians. This achievement highlights the company's significant impact on health access over its 20-year history. Key growth metrics include a 4x increase in primary care visits year-to-date and a 30% rise in nutrition consultations. Additionally, 34% of patients in chronic condition management are utilizing multiple programs. The company has gained recognition in 2022, being named among America's Most Trusted Companies by Newsweek.

Teladoc Health reported a 17% year-over-year revenue increase to $611.4 million for Q3 2022 and a net loss of $73.5 million or $0.45 per share. Adjusted EBITDA fell 24% to $51.2 million. The company's cash flow from operations for the quarter was $63.0 million. U.S. revenues grew 17% while international revenues matched this growth. Despite the revenue growth, stock-based compensation and amortization charges contributed heavily to the net loss. For Q4, Teladoc expects revenue of $625 - $640 million.

Teladoc Health (NYSE: TDOC) has appointed Laizer Kornwasser as President of Enterprise Growth and Global Markets, effective October 24, 2022. Kornwasser will focus on enhancing revenue and profit from the company's whole-person care strategy across various client channels, including US Group Health and BetterHelp. With over 20 years in healthcare, he previously led CareCentrix and held positions at Medco. CEO Jason Gorevic highlighted Kornwasser's expertise in driving growth and managing teams as vital for strengthening Teladoc's market position.